Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - July 2016

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Brivaracetam (Briviact®) has been accepted for restricted use as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy. The restriction limits use to patients with refractory epilepsy and treatment should be initiated by physicians who have appropriate experience in the treatment of epilepsy.

Vortioxetine (Brintellix®) has been accepted for restricted use in the treatment of major depressive episodes in adults. The restriction limits use to patients who have experienced an inadequate response (either due to lack of adequate efficacy and/or safety concerns/intolerability) to two or more previous antidepressants.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - July 2016' on Email Share 'SMC Update - July 2016' on Delicious Share 'SMC Update - July 2016' on Digg Share 'SMC Update - July 2016' on Facebook Share 'SMC Update - July 2016' on Google+ Share 'SMC Update - July 2016' on reddit Share 'SMC Update - July 2016' on StumbleUpon Share 'SMC Update - July 2016' on Twitter

atomic-wealth

No Comments to “SMC Update - July 2016”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,211 spam comments.

atomic-wealth
fond-illness
summer